留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

蒋琰,  盛春泉,  董国强

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(4): 303-308,379
蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
引用本文: 蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu
JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
Citation: JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.004

  • 第二军医大学药学院药物化学教研室, 上海 200433

Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors

  • Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 拓扑异构酶(topoisomerases,Tops)是参与调节细胞内DNA复制、转录、重组和修复等过程的必需酶。Tops分为TopⅠ和TopⅡ,两者通过DNA切断和连接,维持DNA正常拓扑结构和代谢过程。由于Tops在DNA代谢过程的重要作用,干扰Tops的催化活性或者诱导产生Tops介导的DNA损伤已经成为抗肿瘤治疗的重要策略。Tops已经成为最重要的抗肿瘤靶点之一。综述近年来Tops双重抑制剂的研究进展。
    Abstract: DNA topoisomerases (Tops) are essential enzymes that regulate the cellular processes such as replication, transcription, recombination and repair. DNA Tops can be classified into two types, topoisomerase Ⅰ (TopⅠ) and topoisomerase Ⅱ (TopⅡ). They catalyze the breakage and religation of DNA, maintaining the topological changes of DNA and various DNA metabolic processes. Due to their important role in DNA metabolism, the ability to interfere with the functions of Tops or generating Top-mediated DNA damage is an effective strategy for cancer chemotherapy. Tops have been considered as the most important targets for tumor chemotherapy. In this review, we used examples to describe the development of dual topoisomerase Ⅰ and Ⅱ inhibitors.
  • [1] Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents Ⅰ. The isolation and structure of camptothecin, a noveⅠ alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1,2[J]. J Am Chem Soc, 1966, 88(16): 3888-3890.
    [2] Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase Ⅰ[J]. J Biol Chem, 1985, 260(27): 14873-14878.
    [3] Dallavalle S, Gattinoni S, Mazzini S, et al. Synthesis and cytotoxic activity of a new series of topoisomerase Ⅰ inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(4): 1484-1489.
    [4] Kruczynski A, Barret JM, Van Hille B, et al. Decreased nucleotide excision repair activity and alterations of topoisomerase Ⅱ alpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases Ⅰ and Ⅱ[J]. Clin Cancer Res, 2004, 10(9): 3156(3168.
    [5] Kluza J, Mazinghien R, Irwin H, et al. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL(60 leukemia cells with tafluposide or etoposide[J]. Anticancer Drugs, 2006, 17(2): 155(164.
    [6] Mucci(LoRusso P, Polin L, Bissery MC, et al. Activity of batracylin (NSC-320846) against solid tumors of mice[J]. Invest New Drugs, 1989, 7(4): 295-306.
    [7] Plowman J, Paull KD, Atassi G, et al. Preclinical antitumor activity of batracylin (NSC 320846)[J]. Invest New Drugs, 1988, 6(3): 147-153.
    [8] Rao VA, Agama K, Holbeck S, et al. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases Ⅰ and Ⅱ induces histone gamma-H2AX as a biomarker of DNA damage[J]. Cancer Res, 2007, 67(20): 9971-9979.
    [9] Lewis LJ, Mistry P,Charlton PA,et al. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs 2007, 18, 139-48.
    [10] de Jonge MJ, Kaye S, Verweij J, et al. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase Ⅰ and Ⅱ inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours[J]. Br J Cancer, 2004, 91(8): 1459-1465.
    [11] Verborg W, Thomas H, Bissett D, et al. First-into-man phase Ⅰ and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action[J]. Br J Cancer, 2007, 97(7): 844-850.
    [12] Montaner B, Castillo-Avila W, Martinell M, et al. DNA interaction and dual topoisomerase Ⅰ and Ⅱ inhibition properties of the anti-tumor drug prodigiosin[J]. Toxicol Sci, 2005, 85(2): 870-879.
    [13] Montaner B, Navarro S, Pique M, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines[J]. Br J Pharmacol, 2000, 131(3): 585-593.
    [14] Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells[J]. Life Sci, 2001, 68(17): 2025-2036.
    [15] Lin JK. Molecular targets of curcumin[J]. Adv Exp Med Biol, 2007, 595: 227-243.
    [16] Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase Ⅰ-and Ⅱ-DNA complexes in K562 leukemia cells[J]. J Nat Prod, 2007, 70(12): 1884-1888.
    [17] Dhandapani KM, Mahesh VB,Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-Ⅰ and NF kappaB transcription factors[J]. J Neurochem, 2007, 102(2): 522-538.
    [18] Chih LL,Jen KL. Curcumin: a potential cancer chemopreventive agent through suppressing NF-κB signaling[J]. J Cancer Mol, 2008, 4(1): 11-16.
    [19] Choi JY, Seo CS, Zheng MS, et al. Topoisomerase Ⅰ and Ⅱ inhibitory constituents from the bark of Tilia amurensis[J]. Arch Pharm Res, 2008, 31(11): 1413-1418.
    [20] Ishiyama D, Kanai Y, Senda H, et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅱ. Structure elucidation[J]. J Antibiot (Tokyo), 2000, 53(9): 873-878.
    [21] Kanai Y,Ishiyama D,Senda H,et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅰ. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J Antibiot (Tokyo) 2000, 53, 863-72.
    [22] Khan QA, Elban MA; Hecht SM. The topopyrones poison human DNA topoisomerases Ⅰ and Ⅱ[J]. J Am Chem Soc, 2008, 130(39): 12888-12889.
    [23] Hecht SM, Khan QA, Maini R, et al. Topopyrones: Dual topoisomerase inhibitors. Patent PCT/US2009/050081, 2010.
    [24] López-Lázaro M, Willmore E,Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases Ⅰ and Ⅱ in cells[J]. Mutat Res, 2010, 696:41-47.
    [25] Demarquay D, Huchet M, Coulomb H, et al. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo[J]. Cancer Res, 2004, 64:4942-4949.
    [26] Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase Ⅰ-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins[J]. J Med Chem, 2000, 43(11): 2285-2289.
    [27] Taniguchi K, Kohno K, Kawanami K, et al. Drug-induced down-regulation of topoisomerase Ⅰ in human epidermoid cancer cells resistant to saintopin and camptothecins[J]. Cancer Res, 1996, 56(10): 2348-2354.
    [28] Basnet A, Thapa P, Karki R, et al. 2,4,6-Trisubstituted pyridines: synthesis, topoisomerase Ⅰ and Ⅱ inhibitory activity, cytotoxicity, and structure-activity relationship[J]. Bioorg Med Chem, 2007, 15(13): 4351-4359.
    [29] Dalla Via L, Magno SM, Gia O, et al. Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties[J]. J Med Chem, 2009, 52(17): 5429-5441.
  • [1] 黄凤爱, 张俊平.  肿瘤免疫检查点PD-1/PD-L1抑制剂的中药活性成分研究进展 . 药学实践与服务, 2023, 41(5): 277-283, 290. doi: 10.12206/j.issn.2097-2024.202208079
    [2] 王冬博, 聂晶, 武慧娜, 孙磊, 刘丽慧, 吴记勇.  铂类抗肿瘤药物耐药机制的研究进展和应对策略 . 药学实践与服务, 2022, 40(4): 302-308. doi: 10.12206/j.issn.1006-0111.202204046
    [3] 韩凌, 孙治国, 鲁莹.  抗肿瘤药物纳米粒载体的制备材料、包载药物及修饰方法 . 药学实践与服务, 2018, 36(4): 307-312,350. doi: 10.3969/j.issn.1006-0111.2018.04.005
    [4] 李晏, 周莉芬, 张斌.  某院抗肿瘤药物临床应用调查分析 . 药学实践与服务, 2016, 34(1): 86-89. doi: 10.3969/j.issn.1006-0111.2016.01.023
    [5] 黄亚辉, 董国强, 张万年, 盛春泉.  酪氨酸-DNA磷酸二酯酶抑制剂的研究进展 . 药学实践与服务, 2015, 33(4): 298-302. doi: 10.3969/j.issn.1006-0111.2015.04.003
    [6] 陈颖, 韩进松, 王重庆, 宋云龙, 周永刚, 朱驹.  PI3K-mTOR双重小分子抑制剂的研究进展 . 药学实践与服务, 2014, 32(5): 332-336,359. doi: 10.3969/j.issn.1006-0111.2014.05.004
    [7] 徐波, 蒋琰, 张万年, 盛春泉.  抗真菌药物靶标及其抑制剂的研究进展 . 药学实践与服务, 2013, 31(5): 321-325,379. doi: 10.3969/j.issn.1006-0111.2013.05.001
    [8] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [9] 李秋明, 李玲.  抗凝药物新焦点——Xa因子直接抑制剂利伐沙班 . 药学实践与服务, 2010, 28(1): 1-2,47.
    [10] 侯雪梅, 崔黎丽, 李国栋, 李卫华.  抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
    [11] 王燕琼, 姜华, 陈敏玲, 李岚, 张春, 蒋樾廉.  几种常用抗肿瘤药物再配制后稳定性概况 . 药学实践与服务, 2007, (6): 401-403.
    [12] 庄东平.  抗肿瘤新药酪氨酸激酶抑制剂STI571研究进展 . 药学实践与服务, 2005, (6): 353-356.
    [13] 罗琼, 何晖, 潘菡清.  抗肿瘤药物在驻济南部队医院的用药分析 . 药学实践与服务, 2002, (1): 32-33.
    [14] 王昌林, 周月芬, 李昱.  喜树碱类抗肿瘤药物研究概况 . 药学实践与服务, 2001, (3): 172-174.
    [15] 李健和, 徐雯, 龙小华, 曾晓丹.  抗肿瘤药在输液中的稳定性及与其它药物的配伍变化 . 药学实践与服务, 1998, (6): 348-353.
    [16] 丁惠萍, 黄平.  抗肿瘤药物的药代动力学及血浓度测定 . 药学实践与服务, 1996, (1): 37-40.
    [17] 姚春芳, 张紫洞.  胃H+/K+转换ATP酶的可逆性抑制剂:一类新的抗分泌药物 . 药学实践与服务, 1994, (1): 5-7.
    [18] 曾明, 张紫洞.  中枢神经系统抑制剂 . 药学实践与服务, 1988, (4): 16-17.
    [19] 黄贤琦.  抗肿瘤药物的缩写 . 药学实践与服务, 1986, (2): 66-68.
    [20] JohnD.Hirsh.  抗肿瘤药物注射外漏的急救处理 . 药学实践与服务, 1985, (3): 24-25.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3096
  • HTML全文浏览量:  474
  • PDF下载量:  906
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-10-15
  • 修回日期:  2014-02-19

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.004
  • 第二军医大学药学院药物化学教研室, 上海 200433
  • 收稿日期: 2013-10-15
  • 修回日期: 2014-02-19

摘要: 拓扑异构酶(topoisomerases,Tops)是参与调节细胞内DNA复制、转录、重组和修复等过程的必需酶。Tops分为TopⅠ和TopⅡ,两者通过DNA切断和连接,维持DNA正常拓扑结构和代谢过程。由于Tops在DNA代谢过程的重要作用,干扰Tops的催化活性或者诱导产生Tops介导的DNA损伤已经成为抗肿瘤治疗的重要策略。Tops已经成为最重要的抗肿瘤靶点之一。综述近年来Tops双重抑制剂的研究进展。

English Abstract

蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
引用本文: 蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu
JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
Citation: JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计